AcquisitionsMay 12, 2026, 07:34 AM
Collegium Completes AZSTARYS Acquisition; Raises 2026 Guidance
AI Summary
Collegium Pharmaceutical completed the acquisition of AZSTARYS, an ADHD medicine, from Corium Therapeutics for approximately $650 million. This strategic move strengthens Collegium's ADHD portfolio and is expected to be immediately accretive, leading to raised 2026 financial guidance. The company now projects total product revenues of $865 to $895 million and adjusted EBITDA of $475 to $500 million. Additionally, Chief Commercial Officer Scott Dreyer and Chief Medical Officer Thomas Smith will depart.
Key Highlights
- Collegium completed the acquisition of AZSTARYS for approximately $650 million in cash.
- The acquisition was funded by $350 million existing cash and $300 million from a delayed draw term loan.
- Raised 2026 total product revenue guidance to $865-$895 million from $805-$825 million.
- Raised 2026 adjusted EBITDA guidance to $475-$500 million from $455-$475 million.
- AZSTARYS is expected to generate $60-$70 million net revenue for the remainder of 2026.
- AZSTARYS generated over 760,000 prescriptions in 2025.
- Expected annual run rate synergies in excess of $50 million within twelve months.
- AZSTARYS has expected patent protection through December 2037.